GLOBUS MEDICAL, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent
GLOBUS MEDICAL, INC. (GMED) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent of 3.90% for the 12-month period ending 2020-12-31, per its 10-K filed 2023-02-21.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2023-02-21
- GLOBUS MEDICAL, INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2020 was 3.90%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month |
|---|---|
| 2020-12-31 | 3.90% 10-K · filed 2023-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |
| GLAUKOS Corp (GKOS) | United States | $9.135B | -43.73 |
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| Penumbra Inc (PEN) | United States | $12.596B | 77.33 |
| MiniMed Group, Inc. (MMED) | United States | $5.748B | -16.85 |
| MERIT MEDICAL SYSTEMS INC (MMSI) | United States | $5.212B | 28.44 |
| TELEFLEX INC (TFX) | United States | $5.093B | -5.44 |
| Solventum Corp (SOLV) | United States | $15.085B | 9.16 |
| HAEMONETICS CORP (HAE) | United States | $4.821B | 36.52 |
| Heartflow, Inc. (HTFL) | United States | $4.225B |